Title: Oregovomab
CAS Registry Number: 213327-37-8
CAS Name: Anti-(human CA125(carbohydrate antigen)) immunoglobulin G1(mouse monoclonal B43.13 g1-chain) disulfide with mouse monoclonal B43.13 k-chain dimer
Trademarks: OvaRex (AltaRex)
Literature References: Murine monoclonal antibody directed against the ovarian tumor associated antigen CA-125; induces tumor specific cellular immune response. Prepn: M. J. Krantz et al., J. Cell Biochem. Suppl. 12E, 139 (1988). Preparative method as radioimmunodiagnostic: V. Capstick et al., Int. J. Biol. Markers 6, 129 (1991). Clinical experience in antiidiotype induction therapy: R. Madiyalakan et al., Hybridoma 14, 199 (1995). Clinical pharmacokinetics: S. A. McQuarrie et al., Nucl. Med. Commun. 18, 878 (1997). Immunopharmacology: B. C. Schultes et al., Hybridoma 18, 47 (1999); A. A. Noujaim et al., Cancer Biother. Radiopharm. 16, 187 (2001). Assay to monitor immune response: B. C. Schultes, T. L. Whiteside, J. Immunol. Methods 279, 1 (2003). Clinical evaluation in ovarian cancer: J. S. Berek et al., J. Clin. Oncol. 22, 3507 (2004); combined with chemotherapy: A. N. Gordon et al., Gynecol. Oncol. 94, 340 (2004). Reviews of development and therapeutic potential: I. Bruckner, IDrugs 4, 457-462 (2001); J. S. Berek Expert Opin. Biol. Ther. 4, 1159-1165 (2004).
Therap-Cat: Antineoplastic, immunomodulator.
Keywords: Antineoplastic; Immunomodulators; Monoclonal Antibodies. |